News from kodiak sciences inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 10, 2022, 16:10 ET Kodiak Sciences Announces First Quarter 2022 Financial Results and Recent Business Highlights

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...

Apr 29, 2022, 05:30 ET Kodiak Sciences Announces Presentation of KSI-301 Phase 2b/3 Study Data in wet AMD at Upcoming Research Conferences

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...

Mar 01, 2022, 16:10 ET Kodiak Sciences Announces Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...

Feb 23, 2022, 06:00 ET Kodiak Sciences Announces Top-Line Results from its initial Phase 2b/3 Study of KSI-301 in Patients with Neovascular (Wet) Age-Related Macular Degeneration

Kodiak Sciences Inc. (Nasdaq: KOD) today announced top-line results from its randomized, double-masked, active comparator-controlled Phase 2b/3...

Feb 03, 2022, 05:30 ET Kodiak Sciences Completes Enrollment in GLEAM and GLIMMER Phase 3 Clinical Trials of KSI-301 in Patients with Diabetic Macular Edema

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...

Jan 03, 2022, 16:05 ET Kodiak Sciences to Present at the 40th Annual J.P. Morgan Healthcare Conference

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...

Dec 16, 2021, 05:30 ET Kodiak Sciences Completes Enrollment in BEACON Phase 3 Clinical Trial of KSI-301 in Patients with Retinal Vein Occlusion

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...

Nov 09, 2021, 16:30 ET Kodiak Sciences Announces Third Quarter 2021 Financial Results and Recent Business Highlights

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...

Nov 08, 2021, 16:05 ET Kodiak Sciences to Present at Upcoming Conferences

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...

Sep 01, 2021, 05:45 ET Kodiak Sciences Announces New Long-Term Performance Incentive Plan

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...

Aug 31, 2021, 05:02 ET Kodiak Sciences to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...

Aug 09, 2021, 16:01 ET Kodiak Sciences Announces Second Quarter 2021 Financial Results and Recent Business Highlights

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...

May 20, 2021, 19:00 ET Kodiak Sciences to Present at Upcoming Conferences

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...

May 10, 2021, 05:30 ET Kodiak Sciences Announces First Quarter 2021 Financial Results and Recent Business Highlights

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...

Apr 21, 2021, 18:59 ET Kodiak Sciences to Present at Upcoming Conferences

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...

Mar 02, 2021, 16:12 ET Kodiak Sciences to Present at Upcoming Conferences

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...

Mar 01, 2021, 05:30 ET Kodiak Sciences Announces Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...

Feb 13, 2021, 08:28 ET Kodiak Sciences Announces 1-Year Durability, Efficacy and Safety Data from Ongoing Phase 1b Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion at the Angiogenesis, Exudation and Degeneration 2021 Annual Meeting

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...

Feb 02, 2021, 07:14 ET Kodiak Sciences Announces Upcoming Presentation of KSI-301 Phase 1b Clinical Study Data at Angiogenesis, Exudation, and Degeneration 2021 - Virtual Edition

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...

Jan 05, 2021, 08:02 ET Kodiak Sciences to Present at the J.P. Morgan Healthcare Conference

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...

Nov 20, 2020, 16:03 ET Kodiak Sciences Announces Closing of $645.0 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...

Nov 17, 2020, 21:02 ET Kodiak Sciences Announces Pricing of $560.9 Million Public Offering of Common Stock

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...

Nov 16, 2020, 16:01 ET Kodiak Sciences Announces Proposed Offering of Common Stock

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...

Nov 16, 2020, 06:53 ET Kodiak Sciences Completes Enrollment of DAZZLE Phase 2b/3 Pivotal Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...

Nov 12, 2020, 16:12 ET Kodiak Sciences to Present at Upcoming Conferences

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics...